DBV Technologies S.A. (NASDAQ:DBVT) Given Average Rating of “Moderate Buy” by Brokerages

DBV Technologies S.A. (NASDAQ:DBVT) has been assigned an average recommendation of “Moderate Buy” from the nine ratings firms that are currently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, one has given a hold rating, four have issued a buy rating and two have assigned a strong buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $40.25.

Several research analysts have recently weighed in on DBVT shares. Guggenheim restated a “buy” rating and issued a $51.00 target price on shares of DBV Technologies in a research note on Monday, May 4th. Citigroup restated an “outperform” rating on shares of DBV Technologies in a research note on Friday, May 1st. Citizens Jmp upped their target price on shares of DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a research note on Friday, May 1st. Finally, Wall Street Zen upgraded shares of DBV Technologies from a “sell” rating to a “hold” rating in a research note on Saturday, May 2nd.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Artisan Partners Limited Partnership bought a new position in DBV Technologies during the 3rd quarter valued at $519,000. DLD Asset Management LP bought a new position in DBV Technologies during the 3rd quarter valued at $250,000. UBS Group AG boosted its stake in DBV Technologies by 165,347.3% during the 4th quarter. UBS Group AG now owns 244,862 shares of the company’s stock valued at $4,694,000 after acquiring an additional 244,714 shares during the last quarter. GAMMA Investing LLC boosted its stake in DBV Technologies by 38.4% during the 4th quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock valued at $51,000 after acquiring an additional 744 shares during the last quarter. Finally, New York State Common Retirement Fund bought a new position in DBV Technologies during the 3rd quarter valued at $34,000. 71.74% of the stock is currently owned by hedge funds and other institutional investors.

DBV Technologies Price Performance

DBVT opened at $18.18 on Monday. DBV Technologies has a 52-week low of $7.53 and a 52-week high of $26.18. The company has a 50 day moving average of $20.14 and a two-hundred day moving average of $19.27. The company has a market cap of $1.08 billion, a P/E ratio of -4.08 and a beta of -0.96.

DBV Technologies (NASDAQ:DBVT) last announced its earnings results on Thursday, April 30th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.42). The firm had revenue of $0.90 million during the quarter, compared to analysts’ expectations of $1.11 million. DBV Technologies had a negative net margin of 2,895.37% and a negative return on equity of 129.88%. Research analysts anticipate that DBV Technologies will post -0.47 earnings per share for the current year.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.